Events in AML-HR trial by ATRA versus not randomization
. | Comparison, % . | . | . | . | |
|---|---|---|---|---|---|
. | ATRA . | No ATRA . | OR/HR (95% CI) . | P . | |
| Reasons for failure | |||||
| Induction death | 8 | 8 | — | — | |
| Resistant disease | 32 | 29 | — | — | |
| CR rate | 60 | 63 | 1.16 (0.74-1.79) | .6 | |
| Outcome after CR* | |||||
| Death in CR | 28 | 30 | — | .7 | |
| Relapse rate | 59 | 59 | — | .5 | |
| Disease-free survival* | 29 | 29 | 1.12 (0.82-1.53) | .5 | |
| Overall survival* | 21 | 24 | 1.23 (0.97-1.56) | .09 | |
. | Comparison, % . | . | . | . | |
|---|---|---|---|---|---|
. | ATRA . | No ATRA . | OR/HR (95% CI) . | P . | |
| Reasons for failure | |||||
| Induction death | 8 | 8 | — | — | |
| Resistant disease | 32 | 29 | — | — | |
| CR rate | 60 | 63 | 1.16 (0.74-1.79) | .6 | |
| Outcome after CR* | |||||
| Death in CR | 28 | 30 | — | .7 | |
| Relapse rate | 59 | 59 | — | .5 | |
| Disease-free survival* | 29 | 29 | 1.12 (0.82-1.53) | .5 | |
| Overall survival* | 21 | 24 | 1.23 (0.97-1.56) | .09 | |
For ATRA, the number of patients randomly assigned to the group was 180; for no ATRA, it was 182.
— indicates not calculated.
Outcome at 4 years is given for time-to-event end points.